Somatropin biobetter - HanAll Biopharma
Alternative Names: HanTropin; hGH - HanAll BioPharma; HL 032; Oral hGH - HanAll Biopharma; Resist-hGH; VitatropinLatest Information Update: 11 Sep 2017
At a glance
- Originator Nautilus Biotech
- Developer HanAll Biopharma
- Class Biobetters; Growth hormones; Hormonal replacements
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 11 Sep 2017 Discontinued - Phase-I for Somatotropin deficiency (In volunteers) in South Korea (PO)
- 13 Jan 2016 Phase I development is ongoing in South Korea
- 31 Jan 2012 HanAll BioPharma completes a phase I trial in Somatotropin deficiency in South Korea (NCT01440686)